The discovery and development of perampanel for the treatment of epilepsy

The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs

(2014) Karolina M. Stępień et al.   Pharmacological Reports

Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures

(2013) D. Ko et al.   ACTA NEUROLOGICA SCANDINAVICA

Safety and tolerability of perampanel: a review of clinical trial data

(2013) J. M. Serratosa et al.   ACTA NEUROLOGICA SCANDINAVICA

Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist

(2013) M. A. Rogawski et al.   ACTA NEUROLOGICA SCANDINAVICA

Longitudinal cohort studies of the prognosis of epilepsy: contribution of the National General Practice Study of Epilepsy and other studies

(2013) S. D. Shorvon et al.   BRAIN

Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies

(2013) Bernhard J. Steinhoff et al.   EPILEPSIA

Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures

(2013) Barry E. Gidal et al.   EPILEPSIA

Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305

(2012) Jacqueline A. French et al.   EPILEPSIA

Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results from phase III, extension study 307

(2012) Gregory L. Krauss et al.   EPILEPSIA

Discovery of 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (Perampanel): A Novel, Noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropanoic Acid (AMPA) Receptor Antagonist

(2012) Shigeki Hibi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Perampanel—new promise for refractory epilepsy?

(2012) Wolfgang Löscher et al.   Nature Reviews Neurology

A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus

(2012) Laura Ceolin et al.   NEUROCHEMISTRY INTERNATIONAL

Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304

(2012) J. A. French et al.   NEUROLOGY

Randomized phase III study 306: Adjunctive perampanel for refractory partial-onset seizures

(2012) G. L. Krauss et al.   NEUROLOGY

Tolerability and safety of perampanel: two randomized dose-escalation studies

(2011) G. L. Krauss et al.   ACTA NEUROLOGICA SCANDINAVICA

Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy

(2011) Takahisa Hanada et al.   EPILEPSIA

Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial

(2011) Patrick Kwan et al.   LANCET NEUROLOGY

Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease

(2011) Andrew Lees et al.   MOVEMENT DISORDERS

Therapeutic window of opportunity for the neuroprotective effect of valproate versus the competitive AMPA receptor antagonist NS1209 following status epilepticus in rats

(2011) Melanie Langer et al.   NEUROPHARMACOLOGY

Estimation of the burden of active and life-time epilepsy: A meta-analytic approach

(2010) Anthony K. Ngugi et al.   EPILEPSIA

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

(2009) Robert M. Pascuzzi et al.   Amyotrophic Lateral Sclerosis

Rational polytherapy

(2009) Jacqueline A. French et al.   EPILEPSIA

Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial

(2009) Stuart A. Grossman et al.   JOURNAL OF CLINICAL ONCOLOGY

Early Alterations of AMPA Receptors Mediate Synaptic Potentiation Induced by Neonatal Seizures

(2008) S. N. Rakhade et al.   JOURNAL OF NEUROSCIENCE